Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823044 | 0.93 | RAF1 (0.64) | BRAFRAF1 | |
| SCHEMBL1505994 | 0.91 | RAF1 (0.58) | BRAFRAF1 | |
| SCHEMBL29450569 | 0.91 | RAF1 (0.58) | BRAFRAF1 | |
| SCHEMBL1826622 | 0.87 | BRAF (0.56) | BRAFRAF1 | |
| SCHEMBL1825684 | 0.86 | BRAF (0.52) | BRAFRAF1 | |
| SCHEMBL1823795 | 0.85 | BRAF (0.49) | BRAFRAF1 | |
| SCHEMBL1821921 | 0.84 | EGFR (0.50) | BRAFRAF1 | |
| SCHEMBL15051811 | 0.84 | RAF1 (1.00) | BRAFRAF1 | |
| SCHEMBL13292198 | 0.82 | BRAF (0.59) | BRAFRAF1 | |
| SCHEMBL15051369 | 0.82 | RAF1 (1.00) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | BRAF 2068/4885RAF1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.